Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2017 now is available at the company’s website: www.medivir.com
In 2017, Medivir could present groundbreaking results from the company's first phase IIa study with MIV-711 for the treatment of osteoarthritis. In oncology, Medivir's focus area, strong phase II data were presented for remetinostat against Cutaneous T-cell Lymphoma. Furthermore, during the year a phase I/II study with birinapant was initiated in combination with Merck's Keytruda® for the treatment of advanced solid tumors. The preclinical projects developed well during the year. This and much more can be found in Medivir's Annual Report for 2017, published today at www.medivir.com
For further information, please contact:
Erik Björk, CFO Medivir AB, phone: +46 (0)72 228 2831
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.